Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:48:59 UTC |
---|
HMDB ID | HMDB0000077 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Dehydroepiandrosterone |
---|
Description | Dehydroepiandrosterone (DHEA) is a natural steroid hormone produced from cholesterol by the adrenal glands. DHEA is also produced in the gonads, adipose tissue, and the brain. DHEA is structurally similar to and is a precursor of, androstenedione, testosterone, estradiol, estrone, and estrogen. It is the most abundant hormone in the human body. Most of DHEA is sulfated (dehydroepiandrosterone sulfate or DHEA-S) before secretion. DHEA-S is the sulfated version of DHEA; this conversion is reversibly catalyzed by sulfotransferase (SULT2A1) primarily in the adrenals, the liver, and small intestines. In blood, most DHEA is found as DHEA-S with levels that are about 300 times higher than free DHEA. Blood measurements of DHEA-S/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of congenital adrenal hyperplasia. Women with polycystic ovary syndrome tend to have normal or mildly elevated levels of DHEA-S. |
---|
Structure | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1 |
---|
Synonyms | Value | Source |
---|
3-BETA-HYDROXY-5-androsten-17-one | ChEBI | 3beta-Hydroxyandrost-5-en-17-one | ChEBI | Dehydroisoandrosterone | ChEBI | DHA | ChEBI | DHEA | ChEBI | Intrarosa | ChEBI | Prasterone | ChEBI | Biolaif | Kegg | 3-b-HYDROXY-5-androsten-17-one | Generator | 3-Β-hydroxy-5-androsten-17-one | Generator | 3b-Hydroxyandrost-5-en-17-one | Generator | 3Β-hydroxyandrost-5-en-17-one | Generator | (+)-Dehydroisoandrosterone | HMDB | (3-beta)-3-Hydroxyandrost-5-en-17-one | HMDB | (3beta)-3-Hydroxy-androst-5-en-17-one | HMDB | (3beta,16alpha)-3,16-Dihydroxy-androst-5-en-17-one | HMDB | 17-Chetovis | HMDB | 17-Hormoforin | HMDB | 3-beta-Hydroxyandrost-5-en-17-one | HMDB | 3b-Hydroxy-D5-androsten-17-one | HMDB | 3beta-Hydroxy-5-androsten-17-one | HMDB | 3beta-Hydroxy-androst-5-en-17-one | HMDB | 3beta-Hydroxy-D5-androsten-17-one | HMDB | 5,6-Dehydroisoandrosterone | HMDB | 5,6-Didehydroisoandrosterone | HMDB | 5-Androsten-3-beta-ol-17-one | HMDB | 5-Androsten-3b-ol-17-one | HMDB | 5-Androsten-3beta-ol-17-one | HMDB | 5-Dehydro-epiandrosterone | HMDB | 5-Dehydroepiandrosterone | HMDB | Andrestenol | HMDB | Androst-5-ene-3b-ol-17-one | HMDB | Androst-5-ene-3beta-ol-17-one | HMDB | Androsten-3beta-ol-17-one | HMDB | Androstenolone | HMDB | Astenile | HMDB | D5-Androsten-3b-ol-17-one | HMDB | D5-Androsten-3beta-ol-17-one | HMDB | Deandros | HMDB | Dehydro-epi-androsterone | HMDB | Diandron | HMDB | Diandrone | HMDB | Hydroxyandrostenone | HMDB | Prasterona | HMDB | Prasteronum | HMDB | Prestara | HMDB | Psicosterone | HMDB | trans-Dehydroandrosterone | HMDB | Prasterone, 3 alpha-isomer | HMDB | 5 Androsten 3 beta hydroxy 17 one | HMDB | 5-Androsten-3-beta-hydroxy-17-one | HMDB | 5 Androsten 3 ol 17 one | HMDB | Prasterone, 3 alpha isomer | HMDB | 5-Androsten-3-ol-17-one | HMDB | EM-760Dehydroandrosterone | HMDB |
|
---|
Chemical Formula | C19H28O2 |
---|
Average Molecular Weight | 288.4244 |
---|
Monoisotopic Molecular Weight | 288.20893014 |
---|
IUPAC Name | (1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one |
---|
Traditional Name | (1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one |
---|
CAS Registry Number | 53-43-0 |
---|
SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1 |
---|
InChI Key | FMGSKLZLMKYGDP-USOAJAOKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 3-hydroxy-delta-5-steroid
- 3-hydroxysteroid
- 3-beta-hydroxysteroid
- 3-beta-hydroxy-delta-5-steroid
- Oxosteroid
- 17-oxosteroid
- Hydroxysteroid
- Delta-5-steroid
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Alcohol
- Organooxygen compound
- Organic oxide
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 140 - 141 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.064 mg/mL | Not Available | LogP | 3.23 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dehydroepiandrosterone,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CCC2=O | 2604.0 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2619.5 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2643.4 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2554.7 | Standard non polar | 33892256 | Dehydroepiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2939.8 | Standard polar | 33892256 | Dehydroepiandrosterone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1 | 2860.0 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2894.9 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CC=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3170.3 | Semi standard non polar | 33892256 | Dehydroepiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CC=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2831.4 | Standard non polar | 33892256 | Dehydroepiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CC=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3188.1 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Dehydroepiandrosterone GC-MS (1 MEOX; 1 TMS) | splash10-004i-4920000000-9dc14963a290268534b8 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Dehydroepiandrosterone GC-MS (1 TMS) | splash10-004i-3910000000-2bbc760dbeb7f9f1ebfc | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Dehydroepiandrosterone EI-B (Non-derivatized) | splash10-0abi-1790000000-52f5e67bc4d1fab73561 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dehydroepiandrosterone GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0a4l-6940000000-948ad487c238d48aa9be | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-qTof , Positive-QTOF | splash10-022a-1229000000-5fc1bd40299ad859ad1c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-0fk9-0190000000-66ac82624767dc6821e5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-0w90-1690000000-b3a231fc509b7a34e09c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-08gj-1930000000-309dc082cc36ec9dcd8c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-06sj-2910000000-378638f2a861c948f79d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-0536-3900000000-72e80e1a07c4d3a40a7a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone LC-ESI-QFT , positive-QTOF | splash10-0036-4900000000-26c8272483a80d1b5eab | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone , positive-QTOF | splash10-000i-0290000000-1a3588ca5d5bacb9ad30 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone , positive-QTOF | splash10-0bta-3920000000-2df257db43df6cc86570 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 90V, Positive-QTOF | splash10-0036-4900000000-a5988c20b9c2dcaaa0b0 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 75V, Positive-QTOF | splash10-0536-3900000000-9a88dec56cfcb5147a12 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 45V, Positive-QTOF | splash10-08gj-1930000000-7cae68c709391babec19 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 60V, Positive-QTOF | splash10-06sj-2910000000-370c122c31de467a2a1f | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 35V, Positive-QTOF | splash10-05d1-0930000000-890b3cea5a94fdd69458 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 30V, Positive-QTOF | splash10-0w90-0690000000-cd7d0ebd514f0a8966d6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Dehydroepiandrosterone 15V, Positive-QTOF | splash10-0fk9-0190000000-8d6dc67ca77600c3affa | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 10V, Positive-QTOF | splash10-00dr-0090000000-89da8cb383a0718d9033 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 20V, Positive-QTOF | splash10-00dr-0390000000-e6efd70cef2520255bf5 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 40V, Positive-QTOF | splash10-0udm-4690000000-e304b251e97b02f672ad | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 10V, Positive-QTOF | splash10-00dr-0090000000-89da8cb383a0718d9033 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 20V, Positive-QTOF | splash10-00dr-0390000000-e6efd70cef2520255bf5 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 40V, Positive-QTOF | splash10-0udm-4690000000-e304b251e97b02f672ad | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 10V, Negative-QTOF | splash10-000i-0090000000-7498c93972acc3c16404 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 20V, Negative-QTOF | splash10-000i-0090000000-d3ddffc56e91bed39fc4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dehydroepiandrosterone 40V, Negative-QTOF | splash10-052f-2190000000-15aba54ba135047ffe9a | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | 2018-06-19 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Endoplasmic reticulum
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
---|
Tissue Locations | - Adipose Tissue
- Adrenal Cortex
- Adrenal Gland
- Brain
- Epidermis
- Fibroblasts
- Kidney
- Liver
- Neuron
- Ovary
- Placenta
- Platelet
- Prostate
- Skeletal Muscle
- Testis
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.00173-0.0264 uM | Newborn (0-30 days old) | Female | Normal | | details | Blood | Detected and Quantified | 0.00225-0.0433 uM | Newborn (0-30 days old) | Female | Normal | | details | Blood | Detected and Quantified | 0.020 +/- 0.011 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.0153 +/- 0.00763 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.001 (0.00034-0.0017) uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0087 (0.0035-0.013) uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0146 +/- 0.00451 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.023 (0.005-0.042) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.000700-0.0204 uM | Infant (0-1 year old) | Not Specified | Normal | | details | Blood | Detected and Quantified | 0.00295 +/- 0.00319 uM | Children (1-13 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00101 (0.00002-0.002) uM | Adult (>18 years old) | Not Specified | Normal | | details | Saliva | Detected and Quantified | 0.0033 (0.0024-0.0090) uM | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.0022 (0.0006-0.0273) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 0.10 (0.066-0.17) umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 0.022 (0.017-0.041) umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 0.13 +/- 0.057 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.0016 +/- 0.00026 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.00250-0.00284 uM | Adult (>18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.0103 +/- 0.0100 uM | Newborn (0-30 days old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00520 +/- 0.00740 uM | Children (1-13 years old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.052 uM | Adult (>18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.653 uM | Adolescent (13-18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00157-0.385 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0226-0.407 uM | Newborn (0-30 days old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00150 +/- 0.00120 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0120 +/- 0.00700 uM | Adult (>18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0140 +/- 0.00700 uM | Adult (>18 years old) | Female | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00800 +/- 0.0100 uM | Infant (0-1 year old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | <0.00003 uM | Adult (>18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | <0.00003 uM | Adolescent (13-18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | 0.0184-0.0333 uM | Adult (>18 years old) | Female | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00240-0.00830 uM | Infant (0-1 year old) | Both | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis | | details | Blood | Detected and Quantified | 0.0016 uM | Children (1-13 years old) | Female | Aromatase deficiency | | details | Blood | Detected and Quantified | 0.0448 +/- 0.0655 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00246 +/- 0.00350 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00101 uM | Newborn (0-30 days old) | Female | Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete | | details | Blood | Detected and Quantified | 0.0042 uM | Newborn (0-30 days old) | Female | Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00114 +/- 0.000630 uM | Adult (>18 years old) | Not Specified | Leuprolide acetate-induced hypogonadism | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00127 +/- 0.00128 uM | Adult (>18 years old) | Not Specified | Leuprolide acetate-induced hypogonadism with testosterone replacment | | details | Urine | Detected and Quantified | 0.00032 +/- 0.000065 umol/mmol creatinine | Adult (>18 years old) | Both | Rheumatoid arthritis | | details | Urine | Detected and Quantified | 0.00066 +/- 0.00021 umol/mmol creatinine | Adult (>18 years old) | Both | Rheumatoid arthritis | | details | Urine | Detected and Quantified | 0.00034 +/- 0.000078 umol/mmol creatinine | Adult (>18 years old) | Both | Systemic lupus erythematosus (SLE) | | details | Urine | Detected and Quantified | 0.0011 +/- 0.00026 umol/mmol creatinine | Adult (>18 years old) | Both | Systemic lupus erythematosus (SLE) | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency |
---|
- Hattori N, Ishihara T, Moridera K, Hino M, Ikekubo K, Kurahachi H: A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency. Endocr J. 1993 Feb;40(1):107-9. [PubMed:7951484 ]
- Lutfallah C, Wang W, Mason JI, Chang YT, Haider A, Rich B, Castro-Magana M, Copeland KC, David R, Pang S: Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2002 Jun;87(6):2611-22. doi: 10.1210/jcem.87.6.8615. [PubMed:12050224 ]
- Benkert AR, Young M, Robinson D, Hendrickson C, Lee PA, Strauss KA: Severe Salt-Losing 3beta-Hydroxysteroid Dehydrogenase Deficiency: Treatment and Outcomes of HSD3B2 c.35G>A Homozygotes. J Clin Endocrinol Metab. 2015 Aug;100(8):E1105-15. doi: 10.1210/jc.2015-2098. Epub 2015 Jun 16. [PubMed:26079780 ]
| Aromatase deficiency |
---|
- Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H: Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab. 1997 Jun;82(6):1739-45. doi: 10.1210/jcem.82.6.3994. [PubMed:9177373 ]
| 21-Hydroxylase deficiency |
---|
- Gmyrek GA, New MI, Sosa RE, Poppas DP: Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics. 2002 Feb;109(2):E28. [PubMed:11826238 ]
| Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis |
---|
- Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res. 2006 Feb;59(2):276-80. doi: 10.1203/01.pdr.0000195825.31504.28. [PubMed:16439592 ]
| Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete |
---|
- Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, Miller WL: Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. 2008 Mar;93(3):696-702. doi: 10.1210/jc.2007-2330. Epub 2008 Jan 8. [PubMed:18182448 ]
| Lipoid Congenital Adrenal Hyperplasia |
---|
- Fujieda K, Tajima T, Nakae J, Sageshima S, Tachibana K, Suwa S, Sugawara T, Strauss JF 3rd: Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest. 1997 Mar 15;99(6):1265-71. doi: 10.1172/JCI119284. [PubMed:9077535 ]
| Rheumatoid arthritis |
---|
- Straub RH, Weidler C, Demmel B, Herrmann M, Kees F, Schmidt M, Scholmerich J, Schedel J: Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004 Aug;63(8):961-8. [PubMed:15249323 ]
|
|
---|
Associated OMIM IDs | - 201810 (Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency)
- 613546 (Aromatase deficiency)
- 201910 (21-Hydroxylase deficiency)
- 201750 (Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis)
- 613743 (Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete)
- 201710 (Lipoid Congenital Adrenal Hyperplasia)
- 180300 (Rheumatoid arthritis)
|
---|
External Links |
---|
DrugBank ID | DB01708 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB021808 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 8036443 |
---|
KEGG Compound ID | C01227 |
---|
BioCyc ID | 3-BETA-HYDROXYANDROST-5-EN-17-ONE |
---|
BiGG ID | 37131 |
---|
Wikipedia Link | Dehydroepiandrosterone |
---|
METLIN ID | 5133 |
---|
PubChem Compound | 5881 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 28689 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | DHEA |
---|
MarkerDB ID | MDB00000041 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Nguyen Xuan Cuong; Nguyen Van Dan. Synthesis of dehydroepiandrosterone (DHA) from 16-dehydropregnenolone acetate (DPA). Tap Chi Duoc Hoc (1983), (4), 12-14. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Schwarz S, Pohl P: Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992 Feb;55(2):174-82. [PubMed:1620285 ]
- Robinzon B, Michael KK, Ripp SL, Winters SJ, Prough RA: Glucocorticoids inhibit interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandrosterone: a role for 11beta-hydroxysteroid dehydrogenases? Arch Biochem Biophys. 2003 Apr 15;412(2):251-8. [PubMed:12667489 ]
- Rao MS, Subbarao V, Yeldandi AV, Reddy JK: Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res. 1992 May 15;52(10):2977-9. [PubMed:1316232 ]
- Saruc M, Yuceyar H, Ayhan S, Turkel N, Tuzcuoglu I, Can M: The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women--a hyperinsulinemic euglycemic insulin clamp study. Hepatogastroenterology. 2003 May-Jun;50(51):771-4. [PubMed:12828082 ]
- Bamberg E, Aichinger A, Mitteregger G: In vitro metabolism of dehydroepiandrosterone and testosterone by canine hair follicle cells. Vet Dermatol. 2004 Feb;15(1):19-24. [PubMed:14989701 ]
- Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW: Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res. 1990 Jul 1;50(13):3859-62. [PubMed:2141293 ]
- Weill-Engerer S, David JP, Sazdovitch V, Liere P, Schumacher M, Delacourte A, Baulieu EE, Akwa Y: In vitro metabolism of dehydroepiandrosterone (DHEA) to 7alpha-hydroxy-DHEA and Delta5-androstene-3beta,17beta-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Res. 2003 Apr 18;969(1-2):117-25. [PubMed:12676372 ]
- Finlay EM, Morton MS, Gaskell SJ: Identification and quantification of dehydroepiandrosterone sulphate in saliva. Steroids. 1982 Jan;39(1):63-71. [PubMed:6210977 ]
- Uzieblo-Zyczkowska B, Sidlo E, Stelmaszuk T: [Dehydroepiandrosterone (DHEA)--slows down the aging process?]. Pol Merkur Lekarski. 2005 Dec;19(114):831-4. [PubMed:16521435 ]
- Prost O, Nicollier M, Laurent R, Adessi GL: Estrone- and dehydroepiandrosterone-sulfatase activities in human female epidermis. Arch Dermatol Res. 1985;277(3):195-200. [PubMed:3160310 ]
- Friess E, Schiffelholz T, Steckler T, Steiger A: Dehydroepiandrosterone--a neurosteroid. Eur J Clin Invest. 2000 Dec;30 Suppl 3:46-50. [PubMed:11281367 ]
- Hakkinen A, Pakarinen A, Hannonen P, Kautiainen H, Nyman K, Kraemer WJ, Hakkinen K: Effects of prolonged combined strength and endurance training on physical fitness, body composition and serum hormones in women with rheumatoid arthritis and in healthy controls. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):505-12. [PubMed:16095120 ]
- Shackleton C, Malunowicz E: Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome. Steroids. 2003 Oct;68(9):707-17. [PubMed:14625002 ]
- Kim SB, Hill M, Kwak YT, Hampl R, Jo DH, Morfin R: Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab. 2003 Nov;88(11):5199-206. [PubMed:14602750 ]
- Chalbot S, Morfin R: Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives. Drug Metab Dispos. 2005 Apr;33(4):563-9. Epub 2005 Jan 13. [PubMed:15650074 ]
- Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH, Prough RA: Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab Dispos. 2004 Mar;32(3):305-13. [PubMed:14977864 ]
- Martina V, Benso A, Gigliardi VR, Masha A, Origlia C, Granata R, Ghigo E: Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf). 2006 Mar;64(3):260-4. [PubMed:16487434 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|